AGENUS INC Payments to Acquire Debt Securities, Available-for-sale
AGENUS INC (AGEN) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-03-16
- AGENUS INC payments to acquire debt securities, available-for-sale for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- AGENUS INC payments to acquire debt securities, available-for-sale for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- AGENUS INC payments to acquire debt securities, available-for-sale for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- AGENUS INC payments to acquire debt securities, available-for-sale for the quarter ending 2023-03-31 was $14.65M, a 193.70% increase year-over-year.
- AGENUS INC payments to acquire debt securities, available-for-sale for fiscal 2025 was $0.00.
- AGENUS INC payments to acquire debt securities, available-for-sale for fiscal 2023 was $14.65M, a 40.53% decline from fiscal 2022.
- AGENUS INC payments to acquire debt securities, available-for-sale for fiscal 2022 was $24.63M, a 64.28% increase from fiscal 2021.
- AGENUS INC payments to acquire debt securities, available-for-sale for fiscal 2021 was $14.99M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-16 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $0.00 derived: sum of 3 quarters · filed 2026-03-16 | $14.65M 10-K · filed 2026-03-16 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $14.65M 10-Q · filed 2024-11-12 | $24.41M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $14.65M 10-Q · filed 2024-08-08 | $24.41M derived: sum of 3 quarters · filed 2025-03-17 | $29.33M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $14.65M 10-Q · filed 2024-05-07 | $24.41M derived: sum of 2 quarters · filed 2025-03-17 | $29.33M derived: sum of 3 quarters · filed 2025-03-17 | $34.29M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $9.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $14.68M derived: sum of 2 quarters · filed 2025-03-17 | $19.64M derived: sum of 3 quarters · filed 2025-03-17 | $24.63M 10-K · filed 2025-03-17 |
| 2022-09-30 | $4.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $9.87M derived: sum of 2 quarters · filed 2023-11-09 | $14.86M 10-Q · filed 2023-11-09 | $24.85M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $4.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $9.95M 10-Q · filed 2023-08-08 | $19.94M derived: sum of 3 quarters · filed 2024-03-14 | |
| 2022-03-31 | $4.99M 10-Q · filed 2023-05-09 | $14.98M derived: sum of 2 quarters · filed 2024-03-14 | ||
| 2021-12-31 | $9.99M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $14.99M 10-K · filed 2024-03-14 | ||
| 2021-09-30 | $5.00M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |